-P R Harrigan Researcher Activity Profile

Research Author Detailed Information 

P R Harrigan Publication Rate By Year

P R Harrigan has published 10 paper(s) in 2007, 4 paper(s) in 2008, for a total of 14 research publications in total.

P R Pr Harrigan Author Information

LAST NAME: harrigan

FIRST NAME: P R

INITIALS: pr

AFFILIATION:

Papers

P R Harrigan's Publication Record

1. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
2. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Year Published: 2007
3. Transmission of drug-resistant HIV-1 from an infected individual to a caregiver. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
4. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Year Published: 2007
5. Transmission of drug-resistant HIV-1 from an infected individual to a caregiver. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC, Canada.
6. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Year Published: 2007
Molecular Interactions Group, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia.
7. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.
8. N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. Year Published: 2007
9. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Year Published: 2008
BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
10. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Year Published: 2007
Molecular Interactions Group, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia.
11. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Year Published: 2007
British Columbia Centre for Excellence in HIV/AIDS, Providence Healthcare, St Paul's Hospital, 667-1081 Burrard Street, Vancouver, BC, Canada.
12. CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naive Individuals. Year Published: 2008
B.C. Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada., Faculty of Medicine, University of British Columbia, British Columbia, Canada.
13. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. Year Published: 2008
B.C. Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.
14. Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. Year Published: 2008
Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.